Key facts
- It has raised $14.9M across 2 recorded rounds; the latest was Seed Round ($1.2M) in Apr 2025.
- Notable investors include Service Provider Capital, Flybridge (New York), XFactor Ventures, 100 Plus Capital, Arizona Tech Investors — 9 tracked in total.
- AltrixBio has filed 2 Form Ds with the SEC, most recently Jun 2025 ($1.2M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for AltrixBio
Funding rounds
2 roundsAbout AltrixBio
Developer of therapeutic drugs designed for controlled gastrointestinal targeting. The company's drugs treat patients with obesity by providing duodenal isolation similar to gastric bypass, restricting the absorption of fats and glucose through the mucosa in the bowels, helping to reduce glucose levels, enabling patients with an oral medication that replicates the metabolic success of bariatric surgery and is more financially feasible than surgery.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 7
- Website
- altrixbio.com/
- Ownership
- Privately Held (backing)
AltrixBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AltrixBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AltrixBio in its N-PORT filings yet. We sweep new filings monthly.